Hydroxyalkyl Starch Selective Macrophage Targeting for Hematological Neoplasms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematological neoplasms, such as leukemia and lymphoma, often result in severe side effects due to the non-selective nature of chemotherapy drugs, which can lead to tumor recurrence during recovery periods.
Innovation Solution
The use of hydroxyalkylated starch (HAS) as a therapeutic agent to reduce tumor growth rate and cancer cell proliferation while minimizing toxic side effects, potentially combined with standard chemotherapy drugs to reduce their dosage and frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemotherapy drugs are used to treat hematological neoplasms, then tumor growth rate and cancer cell proliferation are reduced, but severe toxic side effects occur
Solution Approach 1:
The patent uses hydroxyalkyl starch as an intermediary substance that selectively binds to hematological neoplasm cells through macrophage-mediated recognition. This intermediary approach allows the treatment to target cancer cells indirectly while sparing healthy cells, thereby reducing toxic side effects while maintaining tumor growth reduction efficacy
Solution Approach 2:
The patent changes the parameter of selectivity by using hydroxyalkyl starch with specific molecular weight and substitution degree parameters. These parameter optimizations enable the starch to be recognized by macrophages associated with neoplasm cells, achieving selective targeting without the non-specific toxicity of conventional chemotherapy
2Reliability
If chemotherapy drugs are administered repeatedly to prevent tumor recurrence, then treatment efficacy is maintained, but toxic side effects accumulate and health deteriorates
Solution Approach 1:
By using hydroxyalkyl starch as a repeatable intermediary treatment that accumulates in neoplasm-associated macrophages, the patent enables continuous or repeated administration without cumulative toxicity. The intermediary selectively targets diseased cells, allowing reliable long-term treatment efficacy while avoiding the accumulated harm that plagues conventional chemotherapy
3Productivity
If standard chemotherapy dosage is used to ensure treatment effectiveness, then tumor control is achieved, but recovery periods are required due to toxicity
Solution Approach 1:
The hydroxyalkyl starch intermediary enables continuous treatment without recovery periods because it selectively accumulates only in neoplasm-associated macrophages. This selective intermediary approach maintains effective tumor control while eliminating the toxic recovery intervals required by conventional chemotherapy, allowing uninterrupted treatment duration
Data Source
AI summary
The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.